A61P 7/06
Antianaemics
A61P7/06 (Antianaemics) appears on 5,672 US grants and 9,339 published applications in this corpus.
Search patents in A61P- Granted patents
- 5,672
- Published applications
- 9,339
- Assignees
- 2,498
- Inventors
- 13,550
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 5 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 4 | 0 |
| 1986 | 4 | 0 |
| 1987 | 7 | 0 |
| 1988 | 4 | 0 |
| 1989 | 14 | 0 |
| 1990 | 11 | 0 |
| 1991 | 8 | 0 |
| 1992 | 14 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 11 | 0 |
| 1996 | 18 | 0 |
| 1997 | 31 | 0 |
| 1998 | 55 | 0 |
| 1999 | 51 | 0 |
| 2000 | 49 | 0 |
| 2001 | 60 | 20 |
| 2002 | 75 | 150 |
| 2003 | 83 | 261 |
| 2004 | 72 | 343 |
| 2005 | 75 | 362 |
| 2006 | 130 | 362 |
| 2007 | 143 | 410 |
| 2008 | 170 | 434 |
| 2009 | 197 | 523 |
| 2010 | 302 | 674 |
| 2011 | 300 | 585 |
| 2012 | 356 | 565 |
| 2013 | 364 | 434 |
| 2014 | 382 | 544 |
| 2015 | 375 | 456 |
| 2016 | 350 | 479 |
| 2017 | 339 | 414 |
| 2018 | 281 | 404 |
| 2019 | 282 | 364 |
| 2020 | 250 | 335 |
| 2021 | 204 | 272 |
| 2022 | 165 | 255 |
| 2023 | 122 | 233 |
| 2024 | 123 | 206 |
| 2025 | 108 | 147 |
| 2026 | 61 | 107 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for reducing skin porphyrin content and inciddence of acnes, or increasing ferritin content within intestinal cells by using queen plum extract6 Oct 2026US 12,751,987 B2Tci Co., Ltd.
- Method of treating a blood disorder associated with C1q-mediated activation of the classical complement pathway by administering an anti-C1q antibody15 Sep 2026US 12,735,473 B2Annexon, Inc.
- Compositions and methods for hematopoietic stem cell transplants15 Sep 2026US 12,735,678 B2Orca Biosystems, Inc.
- Optimized lentiviral vector compromising minimal enhancer elements for stem cell gene therapy of hemoglobinopathies1 Sep 2026US 12,723,262 B2The Regents of the University of California
- Crystal form of quinolinone compound and use thereof25 Aug 2026US 12,715,846 B2Sunshine Lake Pharma Co., Ltd.
- (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease8 Oct 2026US 2026/0306503 A1Global Blood Therapeutics, Inc.
- Treating iron deficiency with ferric carboxymaltose24 Sep 2026US 2026/0283998 A1Pharmacosmos Holding A/S
- Anti-tmprss6 antibodies and uses thereof24 Sep 2026US 2026/0286007 A1Disc Medicine, Inc.
- Use of prime editing for treating sickle cell disease17 Sep 2026US 2026/0273100 A1President and Fellows of Harvard College
- Prime editing of single base mutations in sickle cell disease17 Sep 2026US 2026/0273102 A1Beam Therapeutics Inc.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Modified antibody variable domains462US 5,766,886 AXoma Corporation · 1998
- Regulation of endogenous gene expression in cells using zinc finger proteins395US 6,824,978 B1Sangamo BioSciences, Inc. · 2004